These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12616105)

  • 1. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
    Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
    J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
    Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
    Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
    Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
    J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II clinical trial of h-R3 combined radiotherapy for locoregionally advanced nasopharyngeal carcinoma].
    Wu RR; Wu SX; Zhao C; Xie FY; Gao JM; Hu WH; Gao YH; Li FY; Cui TT; Lu TX
    Ai Zheng; 2007 Aug; 26(8):874-9. PubMed ID: 17697551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
    Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
    Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
    Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
    Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats.
    Navarro BG; Parada AC; Alvarez P; Leon A; Santana E; Bada A; Figueredo R; Iznaga-Escobar N; Perez R
    Exp Toxicol Pathol; 2005 Mar; 56(4-5):313-9. PubMed ID: 15816360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
    Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
    J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
    Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
    Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.
    Iznaga Escobar N; Morales AM; Ducongé J; Torres IC; Fernández E; Gómez JA
    Nucl Med Biol; 1998 Jan; 25(1):17-23. PubMed ID: 9466357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
    Ramos TC; Figueredo J; Catala M; González S; Selva JC; Cruz TM; Toledo C; Silva S; Pestano Y; Ramos M; Leonard I; Torres O; Marinello P; Pérez R; Lage A
    Cancer Biol Ther; 2006 Apr; 5(4):375-9. PubMed ID: 16575203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
    Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
    Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
    Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.
    Faillot T; Magdelénat H; Mady E; Stasiecki P; Fohanno D; Gropp P; Poisson M; Delattre JY
    Neurosurgery; 1996 Sep; 39(3):478-83. PubMed ID: 8875477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor.
    Vallis KA; Reilly RM; Chen P; Oza A; Hendler A; Cameron R; Hershkop M; Iznaga-Escobar N; Ramos-Suzarte M; Keane P
    Nucl Med Commun; 2002 Dec; 23(12):1155-64. PubMed ID: 12464779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
    Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
    J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma].
    Huang XD; Yi JL; Gao L; Xu GZ; Jin J; Yang WZ; Lu TX; Wu SX; Wu RR; Hu WH; Xie WC; Han F; Gao YH; Gao JM; Pan JJ; Chen CB; Lang JY; Li T; Dong Y; Fu YB; Fan L; Li BS; Li J; Wang XH; Chen BX; Gao XS; Zhang P; Wu XW; Hu BQ
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):197-201. PubMed ID: 17649636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.
    Wang C; He X; Zhou B; Li J; Li B; Qian W; Hou S; Wang H; Shi Y; Guo Y
    MAbs; 2011; 3(1):67-75. PubMed ID: 21051930
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.